Neose, BioGeneriX face trial delay for GlycoPEG-GCSF

By Elaine Rigoli

Tampa, Fla., Sept. 22 - Neose Technologies, Inc. has been advised that its co-development partner for GlycoPEG-GCSF, BioGeneriX AG, may delay the start of phase 1 clinical trials for the compound unless it secures a financing and development partner.

Neose, a Horsham, Pa.-based biopharmaceutical company, said that under the agreement entered into by Neose and BioGeneriX in April 2004, BioGeneriX is responsible for all clinical development costs, with the exception of the cost of Neose reagent supply.

BioGeneriX has made a submission to the regulatory authority in a Western European country and is awaiting approval to begin a phase 1 trial for GlycoPEG-GCSF.

If BioGeneriX does not start a phase 1 trial in accordance with its diligence obligations under the agreement, worldwide rights to the GlycoPEG-GCSF program will revert to Neose by mid-February 2007, according to a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.